Sunday, March 25, 2012 2:35:08 AM
For comparisons I also added the percentage of the patients with HCV or HBV infection.
The Asian patients are almost all infected with HBV. This does make a difference in their survival.
From the paper, Cantarini et al, American Journal of Gastroenterology, 101, 91-98 (2006),
Effect of the Etiology of Viral Cirrhosis on the Survival of Patients with Hepatocellular Carcinoma.
"In the whole population, patients with hepatitis B tended to have a poor prognosis than those with
hepatitis C (p = 0.160), and this difference became statistically significant among the patients with
an advanced hepatocellular carcinoma (p = 0.025)."
This probably explains the differences between the non-Asian and the Asian trials below.
If bavi + sorafenib shows an increase in survival then I would think the very large Asian market would be in play.
Recent CDMO News
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
